临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Homoharringtonine (CGX-635)
中文名称:高三尖杉酯碱
CAS号:26833-87-4
分子式: C29H39NO9 分子量: 545.62
产品形式: free Base
研发状态: Recruiting
研发用途: Hereditary Hemorrhagic Telangiectasia; Arteriovenous Malformations; Telangiectasia; Epistaxis; GastroIntestinal Bleeding; Cerebral Arteriovenous Malformations; Vascular Malformation
研究机构: Cure HHT; Augusta University; The Cleveland Clinic; Mayo Clinic; Massachusetts General Hospital; Columbia University; Oregon Health and Science University; University of California Los Angeles; University of California San Francisco; University of Colorado Denver; University of North Carolina Chapel Hill; University of Pennsylvania; University of Texas; University of Utah; Washington University School of Medicine; Yale University; Health Resources and Services Administration (HRSA); Children''s Hospital of Philadelphia
研发日期: November 13 2023
研发阶段: --
Homoharringtonine (CGX-635, Omacetaxine mepesuccinate, HHT, Myelostat, NSC 141633), a plant alkaloid with antitumor properties, inhibits protein translation by preventing the initial elongation step of protein synthesis via an interaction with the ribosomal A-site. Homoharringtonine reversiblely inhibits IL-6-induced STAT3 Tyrosine 705 phosphorylation and reduced anti-apoptotic proteins expression.
Indapamide
中文名称:吲达帕胺
CAS号:26807-65-8
分子式: C16H16ClN3O3S 分子量: 365.83
产品形式: free base
研发状态: Unknown status
研发用途: Pharmacogenomics
研究机构: Ain Shams University
研发日期: March 15 2022
研发阶段: Phase 4
Indapamide is a non-thiazide sulphonamide diuretic compound, generally used in the treatment of hypertension, as well as decompensated cardiac failure.
Amoxicillin
中文名称: 阿莫西林
CAS号:26787-78-0
分子式: C16H19N3O5S 分子量: 365.40
产品形式: Free Base
研发状态: Recruiting
研发用途: Penicillin Allergy
研究机构: Geisinger Clinic
研发日期: March 4 2024
研发阶段: Early Phase 1
Amoxicillin (Amoxycillin) is a moderate-spectrum, bacteriolytic, β-lactam antibiotic used to treat bacterial infections caused by susceptible microorganisms.
Canertinib (CI-1033)
中文名称:卡奈替尼
CAS号:267243-28-7
分子式: C24H25ClFN5O3 分子量: 485.94
产品形式: Free Base
研发状态: Completed
研发用途: Lung Neoplasms
研究机构: Pfizer
研发日期: Jan-03
研发阶段: Phase 2
Canertinib (CI-1033, PD183805) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3.
Reparixin (Repertaxin)
CAS号:266359-83-5
分子式: C14H21NO3S 分子量: 283.39
产品形式: free base
研发状态: Recruiting
研发用途: Myelofibrosis (PMF); Post Essential Thrombocythemia Myelofibrosis (ET-MF); Post Polycythemia Vera Related Myelofibrosis (PV-MF)
研究机构: Icahn School of Medicine at Mount Sinai; Dompé Farmaceutici S.p.A
研发日期: June 27 2023
研发阶段: Phase 2
Reparixin (Repertaxin, DF 1681Y) is a potent and specific inhibitor of CXCR1 with IC50 of 1 nM. Reparixin (Repertaxin) inhibits PMN migration induced by CXCL8 (IC50 = 1 nM) and rodent PMN chemotaxis induced by CXCL1 and CXCL2. Repertaxin inhibits the response of human PMN to CXCL1, which interacts with CXCR2 (IC50 = 400 nM).
Endovion (NS 3728)
中文名称:1-(3,5-双(三氟甲基)苯基)-3-(4-溴-2-(2H-四唑-5-基)苯基)脲
CAS号:265646-85-3
分子式: C16H9BrF6N6O 分子量: 495.18
产品形式: Free base
研发状态: Unknown status
研发用途: Metastatic Colorectal Cancer
研究机构: Scandion Oncology A/S; TFS Trial Form Support
研发日期: May 14 2020
研发阶段: Phase 1 : Phase 2
Endovion (NS 3728, SCO-101) is a potent anion channel inhibitor that blocks the Volume Regulated Anion Channels (VRAC).
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
